US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Telix Pharmaceuticals Ltd. (Uplisting)

16.77

-0.5900-3.40%

Post-market: 16.770.00000.00%16:04 EDT

Volume:12.87K

Turnover:217.62K

Market Cap:5.67B

PE:187.40

High:17.19

Open:16.72

Low:16.31

Close:17.36

Loading ...

Overview Company News Filings

Telix Pharmaceuticals' Revenue Soars 62% in Q1; Fiscal 2025 Guidance Reaffirmed

MT Newswires Live

Telix Pharmaceuticals Q1 Revenue Increases; 2025 Revenue Outlook Reaffirmed

MT Newswires Live

Telix Pharmaceuticals Touts Encouraging Data From Investigational Radiation Therapy In Relapsed Brain Cancer Patients

Telix Pharmaceuticals' Potential Brain Cancer Treatment Shows 'Encouraging' Preliminary Results in Study

MT Newswires Live

Telix Pharmaceuticals Reports Promising Results for TLX101 Glioma Therapy

IPAX-Linz Study Reports Promising Efficacy for TLX101 Glioma Therapy Candidate

Telix Pharmaceuticals' Prostate Cancer Imaging Agent Illuccix Gets Marketing Authorization in Sweden

MT Newswires Live

All You Need to Know About Telix Pharmaceuticals Limited (TLX) Rating Upgrade to Buy

Telix Shares May Gain on the Distribution Deal With Cardinal Health

Telix Pharmaceuticals Taps Cardinal Health as Distributor of Prostate Cancer Imaging Agent Gozellix

MT Newswires Live

Telix Selects Cardinal Health for Commercial Distribution of Gozellix in the US

MT Newswires Live

Telix Announces Cardinal Health for Gozellix Commercial Distribution

UBS Remains a Buy on Telix Pharmaceuticals Ltd. (TLPPF)

Telix Pharmaceuticals Sees No Impact on Business, Supply Chain from US Tariffs, Shares Fall 4%

MT Newswires Live

Telix Pharmaceuticals Unaffected by U.S. Trade Tariffs and Chinese Export Controls

Telix Pharmaceuticals Appoints Chief Technology Officer

MT Newswires Live

Press Release: Anne Whitaker Appointed as Non-Executive Director

Telix Pharmaceuticals to Release Shares from Voluntary Escrow

Telix Pharmaceuticals Begins Early Trial of Soft Tissue Sarcoma Therapy

MT Newswires Live

Telix Announces First Patient Dosed in First-in-Human ZOLAR Trial of TLX300-CDx in Advanced Soft Tissue Sarcoma

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/TLX/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"TLX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TLX\",,,,,undefined,":{"symbol":"TLX","market":"US","secType":"STK","nameCN":"Telix Pharmaceuticals Ltd. (Uplisting)","latestPrice":16.77,"timestamp":1749240000000,"preClose":17.36,"halted":0,"volume":12873,"hourTrading":{"tag":"盘后","latestPrice":16.77,"preClose":16.77,"latestTime":"16:04 EDT","volume":34,"amount":578.18,"timestamp":1749240257024},"delay":0,"floatShares":275137421,"shares":338109048,"eps":0.089486,"marketStatus":"Market Closed","change":-0.59,"latestTime":"06-06 16:00:00 EDT","open":16.72,"high":17.1899,"low":16.31,"amount":217616.5022,"amplitude":0.050685,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.089486,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1749456000000},"marketStatusCode":7,"adr":0,"adrRate":1,"listingDate":1718337600000,"exchange":"NASDAQ","adjPreClose":17.36,"preHourTrading":{"tag":"盘前","latestPrice":17.03,"preClose":17.36,"latestTime":"09:28 EDT","volume":200,"amount":3406,"timestamp":1749216480030},"postHourTrading":{"tag":"盘后","latestPrice":16.77,"preClose":16.77,"latestTime":"16:04 EDT","volume":34,"amount":578.18,"timestamp":1749240257024},"volumeRatio":1.2461762087873647},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TLX\",,,,,undefined,":{"symbol":"TLX","floatShares":275137421,"roa":"5.33%","roe":"13.92%","lyrEps":0.093266,"volumeRatio":1.2461762087873647,"shares":338109048,"dividePrice":0,"high":17.1899,"amplitude":0.050685,"preClose":17.36,"low":16.31,"week52Low":13.61,"pbRate":"15.37","psRate":"11.15","week52High":30.36,"institutionHeld":0,"latestPrice":16.77,"eps":0.089486,"divideRate":0,"volume":12873,"delay":0,"ttmEps":0.089486,"open":16.72,"prevYearClose":15.4,"prevWeekClose":16.9899,"prevMonthClose":16.9899,"prevQuarterClose":16.76,"fiveDayClose":16.9899,"twentyDayClose":17.05,"sixtyDayClose":17.16},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TLX\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2529561632","title":"Telix Pharmaceuticals' Revenue Soars 62% in Q1; Fiscal 2025 Guidance Reaffirmed","url":"https://stock-news.laohu8.com/highlight/detail?id=2529561632","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529561632?lang=en_us&edition=fundamental","pubTime":"2025-04-23 06:28","pubTimestamp":1745360882,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals'  unaudited revenue for the first quarter reached AU$186 million, an increase of 62% from AU$115 million in the year-ago period, according to a Tuesday filing with the Australian bourse.This comprised AU$151 million from global sales of Illuccix and AU$33 million from RLS Radiopharmacies, which was acquired in January.The biopharmaceutical company reaffirmed its FY2025 revenue guidance of AU$770 million to AU$800 million. It noted that this will be updated \"at the appropriate time\" to take into account reimbursement for Gozellix in the US and Illuccix in ex-US markets, per the filing.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TLX","TLX.AU"],"gpt_icon":0},{"id":"2529328391","title":"Telix Pharmaceuticals Q1 Revenue Increases; 2025 Revenue Outlook Reaffirmed","url":"https://stock-news.laohu8.com/highlight/detail?id=2529328391","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529328391?lang=en_us&edition=fundamental","pubTime":"2025-04-22 16:49","pubTimestamp":1745311755,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals  reported Q1 unaudited revenue Tuesday of about $186 million, up from $115 million a year earlier.Two analysts polled by FactSet expected $145.3 million.For 2025, the biotech company reaffirmed its previous revenue guidance of $770 million to $800 million.Analysts polled by FactSet expect $770 million.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TLX"],"gpt_icon":0},{"id":"2527228478","title":"Telix Pharmaceuticals Touts Encouraging Data From Investigational Radiation Therapy In Relapsed Brain Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2527228478","media":"Benzinga","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527228478?lang=en_us&edition=fundamental","pubTime":"2025-04-16 22:57","pubTimestamp":1744815426,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals Limited on Tuesday released preliminary results from the Phase 2 IPAX-Linz study of TLX101  in recurrent high-grade glioma , substantiating the patient benefit seen in the IPAX-1 study.IPAX-Linz is a single-arm Phase 2 investigator-initiated trial evaluating the safety, tolerability, and preliminary efficacyof TLX101 therapy in combination with external beam radiation therapy .TLX101  is a systemically administered targeted radiation therapy that targets L-type amino acid transporter 1, which is typically over-expressed in glioblastoma.The target patient population is patients at first or second recurrence with high-grade gliomas , including glioblastoma.Treatment with TLX101 was well tolerated, with no serious adverse events reported.Also Read: Vale Q1 Iron Ore Output Falls 4.5% Amid Heavy Rains, Copper And Nickel Output Gain. IPAX-Linz demonstrated encouraging preliminary efficacy data, indicating a median overall survival  of 12.4 months from the initiation of ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/telix-pharmaceuticals-touts-encouraging-data-145706839.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","TLX","BK4097","OS"],"gpt_icon":0},{"id":"2527825540","title":"Telix Pharmaceuticals' Potential Brain Cancer Treatment Shows 'Encouraging' Preliminary Results in Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2527825540","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527825540?lang=en_us&edition=fundamental","pubTime":"2025-04-16 15:32","pubTimestamp":1744788751,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals  said Tuesday it received \"encouraging\" preliminary results from an eight-patient phase 2 study of TLX101 in combination with radiation therapy as a potential treatment for recurrent high-grade glioma, a form of brain cancer.The company said the study showed a median overall survival of 12.4 months for patients treated with the TLX101-radiation therapy combo compared with 9.9 months for patients treated with radiation alone.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TLX.AU","BK7067","BK4139","TLX"],"gpt_icon":0},{"id":"2527471796","title":"Telix Pharmaceuticals Reports Promising Results for TLX101 Glioma Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2527471796","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527471796?lang=en_us&edition=fundamental","pubTime":"2025-04-16 06:58","pubTimestamp":1744757893,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Telix Pharmaceuticals Ltd. ( ($AU:TLX) ). Telix Pharmaceuticals Limited has announced promising preliminary res...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/telix-pharmaceuticals-reports-promising-results-for-tlx101-glioma-therapy?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/telix-pharmaceuticals-reports-promising-results-for-tlx101-glioma-therapy?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TLX","BK4139"],"gpt_icon":0},{"id":"2527640471","title":"IPAX-Linz Study Reports Promising Efficacy for TLX101 Glioma Therapy Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2527640471","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527640471?lang=en_us&edition=fundamental","pubTime":"2025-04-16 06:37","pubTimestamp":1744756620,"startTime":"0","endTime":"0","summary":"MELBOURNE, Australia and INDIANAPOLIS, April  16, 2025  (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces preliminary results from the Phase","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/15/3062201/0/en/IPAX-Linz-Study-Reports-Promising-Efficacy-for-TLX101-Glioma-Therapy-Candidate.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INN","BK4181","OS","BK4218","BK4526","BK4543","BK4141","ASX","BK4097","TLX","BK4139"],"gpt_icon":0},{"id":"2527419474","title":"Telix Pharmaceuticals' Prostate Cancer Imaging Agent Illuccix Gets Marketing Authorization in Sweden","url":"https://stock-news.laohu8.com/highlight/detail?id=2527419474","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527419474?lang=en_us&edition=fundamental","pubTime":"2025-04-15 23:23","pubTimestamp":1744730601,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals (TLX) said Tuesday its prostate cancer imaging agent Illuccix has received marketing authorization from Sweden's Medical Products Agency.This approval came after recent authorizations in Norway and Denmark, the company said.Price: 16.86, Change: +0.03, Percent Change: +0.15","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TLX","TLX.AU","BK7067","BK4139"],"gpt_icon":0},{"id":"2527115590","title":"All You Need to Know About Telix Pharmaceuticals Limited (TLX) Rating Upgrade to Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2527115590","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527115590?lang=en_us&edition=fundamental","pubTime":"2025-04-15 00:00","pubTimestamp":1744646410,"startTime":"0","endTime":"0","summary":"Investors might want to bet on Telix Pharmaceuticals Limited , as it has been recently upgraded to a Zacks Rank #2 . This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.The power of a changing earnings picture in determining near-term stock price movements makes the Zacks rating system highly useful for individual investors, since it can be difficult to make decisions based on rating upgrades by Wall Street analysts. These are mostly driven by subjective factors that are hard to see and measure in real time.As such, the Zacks rating upgrade for Telix Pharmaceuticals Limited is essentially a positive comment on its earnings outlook that could have a favorable impact on","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/know-telix-pharmaceuticals-limited-tlx-160010240.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TLX","TLX.AU"],"gpt_icon":0},{"id":"2526144813","title":"Telix Shares May Gain on the Distribution Deal With Cardinal Health","url":"https://stock-news.laohu8.com/highlight/detail?id=2526144813","media":"Zacks","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526144813?lang=en_us&edition=fundamental","pubTime":"2025-04-10 01:30","pubTimestamp":1744219800,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals TLX recently announced a major step in expanding access to its next-generation prostate cancer imaging agent, Gozellix, by selecting Cardinal Health CAH as a key U.S. commercial distribution partner. Gozellix, a gallium-68-based PSMA-PET imaging agent, will be supplied as finished unit doses through Cardinal Health’s radiopharmacy network, supporting streamlined delivery to healthcare providers across the country.This move strengthens Telix’s commercial footprint in the United States and reinforces its commitment to advancing precision oncology. With Cardinal Health’s reach, the company aims to improve patient access and operational efficiency as it gears up for a broader rollout.Following the announcement, shares of the company closed flat at $14.31 on Tuesday. In the year-to-date period, TLX shares have lost 5.4% compared with the industry’s 11.4% decline. The S&P 500 decreased 15.6% in the same time frame.In February, the FDA accepted the Biologics License Appl","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/telix-shares-may-gain-distribution-173000390.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1571399168.USD","LU0052756011.USD","LU0240878834.USD","BK4588","LU0162691827.USD","LU0310800965.SGD","LU2764262908.HKD","TLX","LU0006061336.USD","BK4139","LU1267930813.SGD","LU1880398471.USD","LU0889566641.SGD","LU0154236417.USD","LU1267930227.SGD","LU1267930490.SGD","LU0211327993.USD","LU0205193047.USD","LU0211328371.USD","LU0240877869.USD","LU0205194284.USD","ANGO","BK4082","LU2764263039.SGD","BK4585","MASI","LU0128525689.USD","BK4175","LU2720916845.USD","LU0072461881.USD","SG9999001440.SGD","LU0310799852.SGD","LU0792757196.USD","CAH","LU1880398554.USD","LU2764263203.CNY"],"gpt_icon":0},{"id":"2526820081","title":"Telix Pharmaceuticals Taps Cardinal Health as Distributor of Prostate Cancer Imaging Agent Gozellix","url":"https://stock-news.laohu8.com/highlight/detail?id=2526820081","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526820081?lang=en_us&edition=fundamental","pubTime":"2025-04-09 08:19","pubTimestamp":1744157967,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals (ASX:TLX) named New York Stock Exchange-listed healthcare company Cardinal Health as one of the commercial radiopharmaceutical distributors of its prostate cancer imaging agent, ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0310800965.SGD","BK7067","LU0072461881.USD","LU0006061336.USD","LU0792757196.USD","LU0154236417.USD","TLX","TLX.AU","LU0211327993.USD","LU0889566641.SGD","LU1267930490.SGD","LU0162691827.USD","SG9999001440.SGD","LU0052756011.USD","BK4175","LU0211328371.USD","BK4585","LU1267930813.SGD","BK4588","LU1267930227.SGD","CAH","LU1880398471.USD","LU0128525689.USD","LU1571399168.USD","LU1880398554.USD","LU0310799852.SGD"],"gpt_icon":0},{"id":"2525984908","title":"Telix Selects Cardinal Health for Commercial Distribution of Gozellix in the US","url":"https://stock-news.laohu8.com/highlight/detail?id=2525984908","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525984908?lang=en_us&edition=fundamental","pubTime":"2025-04-08 19:08","pubTimestamp":1744110494,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals (TLX) said Tuesday that it has selected Cardinal Health (CAH) as one of its commercial radiopharmaceutical distributors to supply finished unit doses of Gozellix for the treatmen","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0052756011.USD","LU0211327993.USD","LU0128525689.USD","LU0072461881.USD","BK4585","LU1267930813.SGD","CAH","LU0006061336.USD","SG9999001440.SGD","LU0889566641.SGD","LU0310800965.SGD","LU0162691827.USD","LU1880398471.USD","BK7067","LU0154236417.USD","LU0211328371.USD","LU1267930227.SGD","TLX.AU","BK4139","LU1571399168.USD","LU1880398554.USD","BK4588","BK4175","LU0310799852.SGD","LU1267930490.SGD","TLX","LU0792757196.USD"],"gpt_icon":0},{"id":"2525678448","title":"Telix Announces Cardinal Health for Gozellix Commercial Distribution","url":"https://stock-news.laohu8.com/highlight/detail?id=2525678448","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525678448?lang=en_us&edition=fundamental","pubTime":"2025-04-08 18:30","pubTimestamp":1744108200,"startTime":"0","endTime":"0","summary":"MELBOURNE, Australia and INDIANAPOLIS, April  08, 2025  (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that it has selected Cardinal Heal","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/08/3057434/0/en/Telix-Announces-Cardinal-Health-for-Gozellix-Commercial-Distribution.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889566641.SGD","TLX","BK4213","CAH","LU1267930227.SGD","LU0072461881.USD","BK4205","LU1571399168.USD","BK4192","BK4144","TGA","BK4543","LU0211328371.USD","SG9999001440.SGD","LU0162691827.USD","EEA","BK4165","LU0052756011.USD","ADT","LU1880398554.USD","BK4526","BK4141","ASX","BK4233","LU1267930813.SGD","LU0128525689.USD","LU0792757196.USD","LU1267930490.SGD","BK4585","DCP","LU1880398471.USD","UK","BK4175","BK4139","LU0006061336.USD","LU0154236417.USD","BK4528","LU0310799852.SGD","LU0310800965.SGD","LU0211327993.USD","BK4588"],"gpt_icon":0},{"id":"2525820428","title":"UBS Remains a Buy on Telix Pharmaceuticals Ltd. (TLPPF)","url":"https://stock-news.laohu8.com/highlight/detail?id=2525820428","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525820428?lang=en_us&edition=fundamental","pubTime":"2025-04-08 11:35","pubTimestamp":1744083312,"startTime":"0","endTime":"0","summary":"UBS analyst Laura Sutcliffe maintained a Buy rating on Telix Pharmaceuticals Ltd. (TLPPF – Research Report) today and set a price target of A$36.00...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/ubs-remains-a-buy-on-telix-pharmaceuticals-ltd-tlppf?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/ubs-remains-a-buy-on-telix-pharmaceuticals-ltd-tlppf?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TLX","BK4139","TLPPF"],"gpt_icon":0},{"id":"2525052643","title":"Telix Pharmaceuticals Sees No Impact on Business, Supply Chain from US Tariffs, Shares Fall 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2525052643","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525052643?lang=en_us&edition=fundamental","pubTime":"2025-04-07 12:37","pubTimestamp":1744000631,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals  does not expect any material impact on its business or supply chain from the international trade tariffs announced by the US government on April 2, according to a Monday Australian bourse filing.It noted that it had an extensive US-based manufacturing and distribution infrastructure with third-party manufacturing sites and radiopharmacy partner networks. Pharmaceutical products are currently exempt from the tariffs.The firm also said that the Food and Drug Administration continues to process applications and information requests, despite reports of changes at the agency, and that the firm has not been notified of any changes to the timelines for its new drug application for Pixclara or biologics license application for Zircaix.Its shares fell 4% in recent trading on Monday.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","TLX","TLX.AU"],"gpt_icon":0},{"id":"2525054781","title":"Telix Pharmaceuticals Unaffected by U.S. Trade Tariffs and Chinese Export Controls","url":"https://stock-news.laohu8.com/highlight/detail?id=2525054781","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525054781?lang=en_us&edition=fundamental","pubTime":"2025-04-07 12:17","pubTimestamp":1743999474,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals Ltd. ( ($AU:TLX) ) has shared an announcement. Telix Pharmaceuticals Limited has announced that the recent U.S. government tr...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/telix-pharmaceuticals-unaffected-by-u-s-trade-tariffs-and-chinese-export-controls?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/telix-pharmaceuticals-unaffected-by-u-s-trade-tariffs-and-chinese-export-controls?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","TLX"],"gpt_icon":0},{"id":"2525869380","title":"Telix Pharmaceuticals Appoints Chief Technology Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2525869380","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525869380?lang=en_us&edition=fundamental","pubTime":"2025-04-07 07:48","pubTimestamp":1743983321,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals (ASX:TLX) appointed Paul Schaffer as chief technology officer, according to a Monday statement by the company.Schaffer has been the CTO at Artms, which Telix acquired last year, for the past seven years, the company said.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TLX.AU","TLX","BK7067","BK4139"],"gpt_icon":0},{"id":"2524212621","title":"Press Release: Anne Whitaker Appointed as Non-Executive Director","url":"https://stock-news.laohu8.com/highlight/detail?id=2524212621","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524212621?lang=en_us&edition=fundamental","pubTime":"2025-04-04 06:13","pubTimestamp":1743718380,"startTime":"0","endTime":"0","summary":"MELBOURNE, Australia and INDIANAPOLIS, April 04, 2025  -- Telix Pharmaceuticals Limited  today announces the appointment of Anne Whitaker as a Non-Executive Director  based in the United States, effective 7 April 2025 .Ms. Whitaker is a seasoned healthcare leader and advisor with over 30 years' global corporate experience spanning large pharmaceutical, biotech and speciality pharmaceutical companies, including clinical research and manufacturing organizations. She has held Board positions on a range of Nasdaq-listed clinical and commercial stage life sciences companies. Ms. Whitaker is currently serving as a NED at Icon PLC  and is Chair at QurAlis Corporation.Telix Chairman, H Kevin McCann AO, said, \"Anne is an outstanding addition to our Board. She brings industry-relevant expertise across commercial risk management, mergers and acquisitions and Nasdaq governance, with experience across a vast range of global, growth-focused healthcare companies. The Board looks forward to Anne's con","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ICLR","LU1804176565.USD","TQQQ","LU0511384066.AUD","LU0792757196.USD","LU0426417589.USD","BK4121","NVIW.SI","LU2362540622.SGD","BK4141","BK4543","LU2244417387.USD","LU0029864427.USD","NQmain","LU0882574055.USD","LU2362541513.USD","GSK","LU0128525929.USD","LU1121112475.USD","LU2324357040.USD","SQQQ","LU0728928796.USD","PSQ","LU0069063385.USD","LU0426412945.USD","LU0708994859.HKD","LU0994945656.USD",".IXIC","USAW.SI","BK4526","LU2265009873.SGD","QLD","LU0528227936.USD","ASX","GSK.UK","TSYW.SI","LU2362541273.HKD","LU1267930813.SGD","LU1791710400.SGD","QID","LU1267930573.SGD","BK7067","USJW.SI","R","TLX","BK4139","LU0289960550.SGD","MNQmain","TLX.AU"],"gpt_icon":1},{"id":"2524127401","title":"Telix Pharmaceuticals to Release Shares from Voluntary Escrow","url":"https://stock-news.laohu8.com/highlight/detail?id=2524127401","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524127401?lang=en_us&edition=fundamental","pubTime":"2025-04-02 06:17","pubTimestamp":1743545865,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals Ltd. ( ($AU:TLX) ) has provided an update. Telix Pharmaceuticals Limited announced the release of 717,587 ordinary shares fro...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/telix-pharmaceuticals-to-release-shares-from-voluntary-escrow?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/telix-pharmaceuticals-to-release-shares-from-voluntary-escrow?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","TLX"],"gpt_icon":0},{"id":"2524412989","title":"Telix Pharmaceuticals Begins Early Trial of Soft Tissue Sarcoma Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2524412989","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524412989?lang=en_us&edition=fundamental","pubTime":"2025-04-02 04:06","pubTimestamp":1743537980,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals (TLX) administered the first patient dose in an early trial of TLX300-CDx, also known as olaratumab, to treat advanced metastatic soft tissue sarcoma.The trial aims to evaluate t","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","TLX","BK7067","TLX.AU"],"gpt_icon":0},{"id":"2524126511","title":"Telix Announces First Patient Dosed in First-in-Human ZOLAR Trial of TLX300-CDx in Advanced Soft Tissue Sarcoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2524126511","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524126511?lang=en_us&edition=fundamental","pubTime":"2025-04-02 03:30","pubTimestamp":1743535800,"startTime":"0","endTime":"0","summary":"MELBOURNE, Australia, April 02, 2025  -- Telix Pharmaceuticals Limited  today announces that a first patient has been dosed in the Phase 1 ZOLAR1 trial of TLX300-CDx  in patients with advanced, metastatic soft tissue sarcoma  at the Melbourne Theranostic Innovation Centre  in Melbourne, Australia.The aim of the trial is to evaluate the safety, pharmacokinetics, biodistribution and dosimetry, and establish the optimal dose of TLX300-CDx in patients with advanced STS, prior to therapeutic studies, based on a theranostic approach. As part of the study, it is also expected that the patient dosimetry and target expression characteristics will inform the final selection of therapeutic radionuclide for this candidate, in conjunction with currently active non-clinical radiation biology studies.Telix intends to develop a novel targeted radionuclide therapy, specific for PDGFRα, which could be used to treat patients with STS. Telix holds the exclusive worldwide rights to develop and commercializ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/telix-announces-first-patient-dosed-193000667.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["IE00B66KJ199.SGD","XJO.AU","PET","XKO.AU","BK4139","BK7047","BK4543","BK4192","IE0031619046.USD","BK4526","AEIS","BK7039","TLX.AU","IE00B7SZL793.SGD","SEC.AU","BK4157","BK4141","TLX","ASX","PET.AU","BK7067","XAO.AU","IE00B19Z4B17.USD","ASX.AU"],"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":2,"totalSize":119,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TLX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-02-20","symbol":"TLX","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1740027600000,"reportTimeType":"pre","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TLX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"TLX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.6667,"buy":0.3333,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.6667,"analysts":3,"updateTime":1749182400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/TLX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"TLX","date":"2025-06-06","current":173.121803,"percent":0.388489,"low":151.061716,"twenty":167.88049,"median":177.318176,"eighty":187.949592,"high":205.576265,"avg":177.817132,"sd":12.490541,"marketCap":5638091901.1},"quantilePoints":[{"date":"2024-11-15","current":155.824924,"twenty":155.852142,"median":155.89297,"eighty":156.178762,"marketCap":4970652360.72},{"date":"2024-11-22","current":153.647458,"twenty":154.191824,"median":155.858947,"eighty":156.314854,"marketCap":4920980791.17},{"date":"2024-11-29","current":168.345354,"twenty":154.8995,"median":156.063085,"eighty":158.49232,"marketCap":5381208976.41},{"date":"2024-12-06","current":169.502133,"twenty":155.171684,"median":156.641474,"eighty":168.045953,"marketCap":5368295184.8},{"date":"2024-12-13","current":166.916392,"twenty":155.838533,"median":162.3233,"eighty":168.045953,"marketCap":5240175366.69},{"date":"2024-12-20","current":168.345354,"twenty":155.961016,"median":166.508117,"eighty":168.916939,"marketCap":5183140063.85},{"date":"2024-12-27","current":169.774316,"twenty":156.233199,"median":167.052484,"eighty":169.706271,"marketCap":5196235069.7},{"date":"2025-01-03","current":162.241165,"twenty":156.342072,"median":167.052484,"eighty":169.542961,"marketCap":4949346723.31},{"date":"2025-01-10","current":163.261978,"twenty":156.5326,"median":167.392713,"eighty":169.228803,"marketCap":4970930045.19},{"date":"2025-01-17","current":180.956065,"twenty":158.029608,"median":167.50507,"eighty":169.864326,"marketCap":5535715919.89},{"date":"2025-01-24","current":187.353158,"twenty":159.608271,"median":167.889662,"eighty":170.577257,"marketCap":5785750657.37},{"date":"2025-01-31","current":199.670965,"twenty":161.249345,"median":168.229933,"eighty":175.407845,"marketCap":6122321793.53},{"date":"2025-02-07","current":198.349538,"twenty":162.241165,"median":168.549491,"eighty":182.861582,"marketCap":6131109878.71},{"date":"2025-02-14","current":185.473256,"twenty":162.64949,"median":169.046583,"eighty":187.353158,"marketCap":5747906307.1},{"date":"2025-02-21","current":203.261161,"twenty":163.302811,"median":169.706271,"eighty":187.353158,"marketCap":6486347833.54},{"date":"2025-02-28","current":187.883767,"twenty":163.584606,"median":170.12499,"eighty":192.087093,"marketCap":5864055113.17},{"date":"2025-03-07","current":182.602424,"twenty":164.112905,"median":170.795004,"eighty":190.960114,"marketCap":5800401146.04},{"date":"2025-03-14","current":179.829719,"twenty":164.766144,"median":174.911776,"eighty":189.692293,"marketCap":5647282174.13},{"date":"2025-03-21","current":184.714961,"twenty":166.589772,"median":175.670662,"eighty":188.147066,"marketCap":5803981960.09},{"date":"2025-03-28","current":187.327482,"twenty":166.94361,"median":178.971501,"eighty":190.960114,"marketCap":5900183330.18},{"date":"2025-04-04","current":159.860903,"twenty":166.94361,"median":178.262158,"eighty":189.692293,"marketCap":5073492527.81},{"date":"2025-04-11","current":177.179731,"twenty":166.589772,"median":177.679515,"eighty":188.147066,"marketCap":5496976372.28},{"date":"2025-04-17","current":173.797147,"twenty":166.916392,"median":177.619467,"eighty":187.883767,"marketCap":5535140863.85},{"date":"2025-04-25","current":193.309359,"twenty":167.052484,"median":178.059203,"eighty":190.062144,"marketCap":6172717887.8},{"date":"2025-05-02","current":198.453445,"twenty":167.392713,"median":178.295984,"eighty":190.062144,"marketCap":6327668326.52},{"date":"2025-05-09","current":181.396737,"twenty":167.481337,"median":179.235568,"eighty":190.062144,"marketCap":5809793224.05},{"date":"2025-05-16","current":176.029393,"twenty":167.481337,"median":178.295984,"eighty":189.78972,"marketCap":5619140101.04},{"date":"2025-05-23","current":172.647682,"twenty":167.528804,"median":178.059203,"eighty":189.451294,"marketCap":5528513460.13},{"date":"2025-05-30","current":176.779306,"twenty":167.780801,"median":177.456621,"eighty":188.460572,"marketCap":5687082652.57},{"date":"2025-06-06","current":173.121803,"twenty":167.88049,"median":177.318176,"eighty":187.949592,"marketCap":5638091901.1}],"updateTime":1749393308237}}}